GlaxoSmithKline chooses DRS DocXP to improve standards in clinical trial data capture

GlaxoSmithKline chooses DRS DocXP to improve standards in clinical trial data capture
27th January 2010
Research-based pharmaceutical company, GlaxoSmithKline has deployed DocXP®, an intelligent document and data capture solution supplied by global data capture specialists DRS, to improve standards in its clinical trial data capture.

GlaxoSmithKline's first use of DocXP® will be to process a large number of multipage questionnaires over a period of six months to a year, after which it may look to roll out the data capture solution in clinical studies.

DocXP® is a sophisticated, yet easy to use, intelligent data and document capture, processing, archival and retrieval solution that streamlines the document data capture process. Built on industry leading intelligent character, barcode and mark recognition technologies and techniques, DocXP® captures and processes any data from any type of form - whether the data is in pre-defined areas or in different locations on the document.

The DocXP® solution will provide GlaxoSmithKline with a cost-effective mechanism to increase the speed at which the clinical trial data is transferred and captured, reducing the need for manual data entry. It also improves accuracy and streamlines data source verification and authentication procedures.


Additional Information
DRS
DRS has the skills and expertise to manage data capture projects of any size or complexity around the world.  Complete solutions are implemented using the Company's extensive expertise in document design, printing, forms scanning, software, logistics, project management and consultancy.  Visit www.drs.co.uk for more details.

DocXP®
Sophisticated classification technology sets DocXP® apart from all other competing products. Its ability to automatically identify the document type with no pre-configuration makes it one of the leading intelligent document and data capture solutions on the market today.

GlaxoSmithKline
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

For more information please contact:

Katie McBreen or Richard McCann
Friday's Media Group, 18 Soho Square, London, W1D 3QL
Telephone: 0845 500 1140

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.